BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/9/2024 8:41:18 AM | Browse: 350 | Download: 1237
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 96927
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Prospective Study
Article Title Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer
Manuscript Source Unsolicited Manuscript
All Author List Cheng-Wan Zheng, Yun-Mo Yang and Hui Yang
ORCID
Author(s) ORCID Number
Cheng-Wan Zheng http://orcid.org/0009-0003-1720-1036
Yun-Mo Yang http://orcid.org/0009-0009-6573-0817
Hui Yang http://orcid.org/0009-0009-9194-2311
Funding Agency and Grant Number
Corresponding Author Hui Yang, MMed, Chief Physician, Department of Thyroid Surgery, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. yh65011@163.com
Key Words Advanced gastric cancer; Oxaliplatin; Trastuzumab; Serum tumor markers; T lymphocyte subsets; Predictive biomarkers
Core Tip An investigation of the effects of oxaliplatin and trastuzumab combination therapy on serum tumor markers and T lymphocyte subsets in patients with advanced gastric cancer (AGC) revealed significant reductions in carcinoembryonic antigen, cancer antigen 19-9, and cancer antigen 72-4 levels, as well as favorable changes in T cell populations. Patients with significantly decreased tumor marker levels and increased CD4+/CD8+ ratio exhibited better treatment responses. The therapy not only targets tumors but also boosts immune responses in patients with AGC. Serum markers and T cell subsets are potential predictive biomarkers for treatment outcomes in patients with AGC receiving this combined treatment.
Publish Date 2024-09-09 08:41
Citation

Zheng CW, Yang YM, Yang H. Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer. World J Gastrointest Oncol 2024; 16(9): 3905-3912

URL https://www.wjgnet.com/1948-5204/full/v16/i9/3905.htm
DOI https://dx.doi.org/10.4251/wjgo.v16.i9.3905
Full Article (PDF) WJGO-16-3905-with-cover.pdf